Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Background PD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical mechanisms of tumor-induced immune suppression that contribute to immunotherapy resistance. We hypothesized that Gal-3 blockade with belapectin (GR-MD-02) plus anti-PD-1 (pembrolizumab) would enhance tumor respons...

Full description

Bibliographic Details
Main Authors: William L Redmond, Yoshinobu Koguchi, Annah S Rolig, Noriko Iwamoto, Takashi Shimada, Elizabeth R Sturgill, Zhaoyu Sun, Venkatesh Rajamanickam, Brady Bernard, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin
Format: Article
Language:English
Published: BMJ Publishing Group 2021-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/4/e002371.full

Internet

https://jitc.bmj.com/content/9/4/e002371.full

Similar Items